ArticleAntibiotics (Basel, Switzerland)2020
Effect of Antibiotic Susceptibility and
Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 6 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Assessing the non-inferiority of a 10-day compared with a 14-day vonoprazan-amoxicillin dual therapy regimen for H. pylori eradication: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Comparative efficacy and safety of vonoprazan-based dual therapy vs. bismuth-based quadruple therapy forFrontiers in microbiology · 2026Pooled it
- First-line Eradication of Helicobacter pylori Infection with High-Dose Amoxicillin and Vonoprazan: A Systematic Review and Meta-analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Pooled it
- Third-line and rescue therapy for refractoryWorld journal of gastroenterology · 2023Pooled it
- The prevalence of clarithromycin-resistantPeerJ · 2023Pooled it
- Effects of CYP2C19 genetic polymorphisms on the cure rates ofFrontiers in pharmacology · 2022Pooled it
- Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial).Scientific reports · 2024Trial
- Efficacy of a 7-day vonoprazan, sitafloxacin, and amoxicillin triple therapy as a fourth-line salvage regimen for refractory Helicobacter pylori infection.BMC gastroenterology · 2025Article
- Risks of anti-World journal of gastroenterology · 2025Article
- Antibacterial Mechanisms and Clinical Impact of Sitafloxacin.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Comprehensive insights on treatment modalities with conventional and herbal drugs for the treatment of duodenal ulcers.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Current and Future Perspectives on the Management ofAntibiotics (Basel, Switzerland) · 2024Review
- Crises in Antimicrobial Stewardship: Misuse of Clarithromycin forPharmacoepidemiology · 2024Article
- Vonoprazan a novel potassium competitive acid blocker; another leap forward.Przeglad gastroenterologiczny · 2024Article
- Assessments of CYP‑inhibition‑based drug-drug interaction between vonoprazan and poziotinibPharmaceutical biology · 2023Article
- Evaluation of commonly used cardiovascular drugs in inhibiting vonoprazan metabolismFrontiers in pharmacology · 2022Article
- Increased Glycated Hemoglobin but Decreased Cholesterol after a Loss ofJournal of personalized medicine · 2021Article
- Sitafloxacin for Third-LineJournal of clinical medicine · 2021Review
- Influence ofFrontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
methodsA total of 307 Japanese who were genotyped for
resultsThe eradication rate was 84.5% (95% confidence interval [CI]: 78.9-89.1%) using first-line, 92.6% (95% CI: 82.1-97.9%) using second-line and 87.5% (95% CI: 73.1-95.8%) using third-line treatment. Infection with clarithromycin-resistant strains was a predictive factor for failed eradication (odds ratio: 5.788, 95% CI: 1.916-17.485,
conclusionsGenotyping for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.